NY-AUGURY
7.10.2020 15:02:09 CEST | Business Wire | Press release
Augury , a leading AI-based Machine Health solution provider, today announced a major expansion program with customer ICL - a global manufacturer of products based on unique minerals. ICL has seen great success using Augury’s Machine Health solution, avoiding more than $1,000,000 in production losses and downtime costs in only 10 months. As part of the global roll out, Augury's technology will be implemented across ICL factories located in Israel, Europe, North and South America.
Augury’s Machine Health solutions have transformed and improved ICL’s manufacturing operations by reducing unplanned downtime and providing prescriptive insights into the health and performance of ICL’s production assets. The two companies will continue working together to advance ICL’s quality and productivity goals by digitizing ICL’s world class production processes and improving Overall Equipment Effectiveness (OEE) across all facilities.
“ICL is always looking to innovate and improve the way we manufacture and produce our products,” said Eyal Yaffe, VP Operational Excellence & Innovation Potash Division. “Augury’s Machine Health technology has changed the way we approach reliability and maintenance across our organization by improving the predictability and visibility regarding how our machines are actually performing. Expanding this technology to more facilities globally will help us improve our throughput, reliability and overall production capabilities.”
Augury’s end-to-end solution encompasses the benefits of predictive maintenance by providing industry leaders with prescriptive machine health insights to improve machine performance and overall production. Upon installation, machine operators are notified at the first sign of any developing issues with detailed malfunction analysis and maintenance recommendations. Even the slightest changes to a machine’s health status are carefully diagnosed and filtered so customers only receive meaningful and actionable notifications, not noise. These actionable insights help users correct machine malfunctions before they cause unplanned downtime or production delays.
“ICL’s company-wide dedication to improving the reliability, productivity and resiliency of their manufacturing sites through Machine Health has helped them garner transformative results in a short period of time,” said Saar Yoskovitz, co-founder and CEO of Augury. “ICL’s team has been a pleasure to work with and elevating our partnership will only enable us to show greater success together, further proving that Machine Health is a foundational principle of the future of manufacturing.”
To learn more about Augury’s Machine Health solution, visit www.augury.com .
About ICL
ICL Group LTD is a leading global specialty minerals and chemicals company operating bromine, potash and phosphate mineral value chains in a unique, integrated business model. ICL extracts raw materials from its unique mineral assets and utilizes technology and industrial know-how to add value for customers in key agricultural markets worldwide. ICL shares are listed on the New York Stock Exchange and the Tel Aviv stock Exchange (NYSE and TASE: ICL). The company employs over 11,000 people worldwide and its 2019 revenues totaled approximately $5.3 billion. For more information, visit the Company’s website at www.icl-group.com .
About Augury
Augury is building a world where people can always rely on the machines that matter. Augury supports its partners by enabling Digital Transformation through superior insights into the health and performance of the machines they use to make products, deliver services and improve lives. To learn more about Augury’s machine health solutions, visit www.augury.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201007005157/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom